Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. 2012

Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
Division of Nephrology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

OBJECTIVE This study is designed to observe the urinary tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels in patients with lupus nephritis (LN) and to identify new biomarker of lupus nephritis activity. METHODS Study subjects were 46 cases of patients with LN (including 34 of active cases) who underwent routine renal biopsy. Activity and chronicity indexes of LN were assessed using pathological criteria proposed by Hill et al. in 2000. Urinary TWEAK (uTWEAK) level and Monocyte chemoattractant protein-1 (MCP-1) level were detected by ELISA. RESULTS Urinary TWEAK level was significantly higher in active LN group than in non-active LN group. Correlation analysis showed that urinary TWEAK levels were significantly correlated with activity index (r = 0.825, P < 0.01), glomerular activity index (r = 0.754, P < 0.01), and tubulointerstitial qualitative activity index (r = 0.751, P < 0.01), while not significant correlated with chronicity Index (P > 0.05). The association between urinary TWEAK levels and urinary MCP-1 levels were significant in active LN group (r = 0.809, P < 0.01) but not significant in non-active LN group (P > 0.05). CONCLUSIONS uWEAK levels were correlated with all active indexes of LN, suggesting its potential role as novel biomarker of active lupus nephritis.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006651 Histocytochemistry Study of intracellular distribution of chemicals, reaction sites, enzymes, etc., by means of staining reactions, radioactive isotope uptake, selective metal distribution in electron microscopy, or other methods. Cytochemistry
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074049 Cytokine TWEAK A proteolytically-cleaved membrane glycoprotein and member of the TNF superfamily that is highly expressed in a variety of tissues including heart, pancreas, brain, and peripheral blood lymphocytes. The secreted extracellular form is a weak inducer of APOPTOSIS for some cell types and a ligand for the FN14 RECEPTOR. It mediates activation of NF-KAPPA-B and promotes ANGIOGENESIS and proliferation of ENDOTHELIAL CELLS, as well as expression of cytokines involved in INFLAMMATION. Apo3 Ligand,TNF-Related Weak Inducer of Apoptosis,TWEAK Cytokine,Tumor Necrosis Factor Ligand Superfamily Member 12,Cytokine, TWEAK,Ligand, Apo3,TNF Related Weak Inducer of Apoptosis,TWEAK, Cytokine
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
December 2006, Journal of autoimmunity,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
January 2009, Arthritis research & therapy,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
November 2012, Clinical immunology (Orlando, Fla.),
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
August 2007, Annals of the New York Academy of Sciences,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
February 2018, Zeitschrift fur Rheumatologie,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
July 2018, Scandinavian journal of clinical and laboratory investigation,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
April 2001, Nephron,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
March 2014, Reumatismo,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
January 2009, Arthritis research & therapy,
Zhu Xuejing, and Tan Jiazhen, and Li Jun, and Xu Xiangqing, and Yuan Shuguang, and Liu Fuyou
January 2018, The Egyptian journal of immunology,
Copied contents to your clipboard!